The neurostimulation technology that resolves
unfulfilled demands in key medical conditions
Scroll down
We are developing implantable neurostimulation solutions that enable patients living with complete tetraplegia to regain upper limb autonomy.
We are creating the first neurostimulation device that induces ‘selective’ activation of targeted muscles by steering electrical currents through one or a set of nerves.
Tomorrow, patients will be able to recover the functional use of one hand to perform everyday activities, such as grasping an object or even eating with a fork. In the future, our neurostimulation devices will be able to selectively activate any nerve target to potentially treat a variety of pathologies and deficiencies.
The effectiveness of Neurinnov approach has been successfully tested on a preliminary clinical study with results published in Nature Scientific Reports Journal.
A spin-off from INRIA, the French national institute for research in digital science and technology, and the University of Montpelier, Neurinnov was founded in 2018 upon 20+ years’ research and expertise in micro-electronics, software engineering, electrophysiology and function physiology. Through its generic technology platform that adds value creation across many pathologies, Neurinnov is driving forward innovations aimed at addressing unmet needs in healthcare.
Neurinnov founders have vast expertise, culminating in decades of world-class research and development in micro-electronics, software engineering, electrophysiology and sensory-motor system, along with many years of experience leading successful medtech businesses. They have garnered several prestigious awards in research, including the “Grand prix” of the French National Academy of Sciences.
David Andreu, PhD
Co-founder, CTO and General Manager
David is a specialist in AIMD (Active Implantable Medical Device architecture, where he has won awards.
David Guiraud, PhD
Co-founder and CSO
David is a specialist in electrophysiology and highly experienced in conducting clinical trials, including securing ethical committee approval for research.
Contact
Phone: +33 (0)4 34 34 80 28
Email: contact@neurinnov.com